Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model  

作　　者：Sanbao Chai Shuqing Yu Fengqi Liu Zuoxiang Liu Qingqing Yang Feng Sun 

机构地区：[1]Department of Endocrinology and Metabolism,Peking University International Hospital,Beijing 102206,China [2]Department of Epidemiology and Biostatistics,School of Public Health,Peking University Health Science Centre,Beijing 100191,China

出　　处：《Chinese Medical Journal》2023年第1期102-104,共3页中华医学杂志（英文版）

基　　金：National Natural Science Foundation of China(No.72074011)

摘　　要：To the Editor:Incretin-based therapies for type 2 diabetes mellitus(T2DM)include incretin mimetics of glucagonlike peptide-1 receptor agonists(GLP-1 RAs)and incretin enhancers of dipeptidyl peptidase-4(DPP-4)inhibitors.[1]With good hypoglycemic effects of incretin-based drugs that show no weight gain or hypoglycemia risk,these drugs are increasingly used in patients with T2DM.

关 键 词：DRUGS T2DM diabetes 

分 类 号：R587.1[医药卫生—内分泌]